Evidence map›Paper›PMID 38926133›Full record

ArticleJournal of the National Cancer Institute2024

Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report.

Lenka Ilcisin, Ruxu Han, Mark Krailo, David S Shulman, Brent R Weil, Christopher B Weldon, Puja Umaretiya, Rahela Aziz-Bose, Katie A Greenzang, Richard Gorlick and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Lenka IlcisinDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Ruxu HanChildren's Oncology Group, Monrovia, CA, USA.
Mark KrailoChildren's Oncology Group, Arcadia, CA, USA.
David S ShulmanDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Brent R WeilDepartment of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Christopher B WeldonDepartment of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Puja UmaretiyaDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Rahela Aziz-BoseDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Katie A GreenzangDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Richard GorlickDivision of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Damon R ReedDivision of Pediatric Solid Tumors, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
R Lor RandallDepartment of Orthopaedic Surgery, University of California Davis Health, Sacramento, CA, USA.
Helen NadelDivision of Radiology, Lucille Packard Children's Hospital at Stanford University, Stanford, CA, USA.
Odion BinitieDepartment of Surgery, Moffitt Cancer Center, Tampa, FL, USA.
Steven G DuboisDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Katherine A JanewayDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Kira BonaDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5602-7059

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
National Clinical Trials NetworkNational Clinical Trials Network (NCTN) Operations Center U10CA180886NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCTN Statistics & Data Center U10CA180899Operations Center U10CA180886St Baldrick's Foundation
6 · The paper itself

Abstract

backgroundChildren living in poverty and those of marginalized race or ethnicity experience inferior disease outcomes across many cancers. Whether survival disparities exist in osteosarcoma is poorly defined. We investigated the association between race, ethnicity, and proxied poverty exposures and event-free and overall survival for children with nonmetastatic osteosarcoma receiving care on a cooperative group trial.

methodsWe conducted a retrospective cohort study of US patients with nonmetastatic, osteosarcoma aged 5-21 years enrolled on the Children's Oncology Group trial AOST0331. Race and ethnicity were categorized to reflect historically marginalized populations, as Hispanic, non-Hispanic Black, non-Hispanic Other, and non-Hispanic White. Poverty was proxied at the household and neighborhood levels. Overall survival and event-free survival functions of time from trial enrollment were estimated using the Kaplan-Meier method. Hypotheses of associations between risks for event-free survival, death, and postrelapse death with race and ethnicity were assessed using log-rank tests.

resultsAmong 758 patients, 25.6% were household-poverty and 28.5% neighborhood-poverty exposed. Of the patients, 21% of children identified as Hispanic, 15.4% non-Hispanic Black, 5.3% non-Hispanic Other, and 54.0% non-Hispanic White. Neither household or neighborhood poverty nor race and ethnicity were statistically significantly associated with risks for event-free survival or death. Postrelapse risk for death differed statistically significantly across race and ethnicity with non-Hispanic Black patients at greatest risk (4-year postrelapse survival 35.7% Hispanic vs 13.0% non-Hispanic Black vs 43.8% non-Hispanic Other vs 38.9% non-Hispanic White; P = .0046).

conclusionsNeither proxied poverty exposures or race and ethnicity were associated with event-free survival or overall survival, suggesting equitable outcomes following frontline osteosarcoma trial-delivered therapy. Non-Hispanic Black children experienced statistically significant inferior postrelapse survival. Investigation of mechanisms underlying postrelapse disparities are paramount.

Indexed as

Bone NeoplasmsOsteosarcomaPovertyAdolescentBlack or African AmericanChildChild, PreschoolEthnicityFemaleHispanic or LatinoHumansMaleRetrospective StudiesUnited StatesWhiteYoung Adult

Identifiers

PMID38926133
PMCPMC12116299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.